Literature DB >> 26954563

Influenza immunology evaluation and correlates of protection: a focus on vaccines.

Claudia Maria Trombetta1, Emanuele Montomoli1,2.   

Abstract

Vaccination is the most effective method of controlling seasonal influenza infections and preventing possible pandemic events. Although influenza vaccines have been licensed and used for decades, the potential correlates of protection induced by these vaccines are still a matter of discussion. Currently, inactivated vaccines are the most common and the haemagglutination inhibition antibody titer is regarded as an immunological correlate of protection and the best available parameter for predicting protection from influenza infection. However, the assay shows some limitations, such as its low sensitivity to B and avian strains and inter-laboratory variability. Additional assays and next-generation vaccines have been evaluated to overcome the limitations of the traditional serological techniques and to elicit broad immune responses, underlining the need to revise the current correlates of protection. The aim of this review is to provide an overview of the current scenario regarding the immunological evaluation and correlates of protection of influenza vaccines.

Entities:  

Keywords:  Correlates of protection; guidelines on influenza vaccines; haemagglutination inhibition titer; immunological assays; influenza vaccines

Mesh:

Substances:

Year:  2016        PMID: 26954563     DOI: 10.1586/14760584.2016.1164046

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  47 in total

1.  Influenza Hemagglutination-inhibition Antibody Titer as a Mediator of Vaccine-induced Protection for Influenza B.

Authors:  Benjamin J Cowling; Wey Wen Lim; Ranawaka A P M Perera; Vicky J Fang; Gabriel M Leung; J S Malik Peiris; Eric J Tchetgen Tchetgen
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079

2.  Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice.

Authors:  A F Altenburg; S E Magnusson; F Bosman; L Stertman; R D de Vries; G F Rimmelzwaan
Journal:  Clin Exp Immunol       Date:  2017-07-24       Impact factor: 4.330

Review 3.  Distinguishing Causation From Correlation in the Use of Correlates of Protection to Evaluate and Develop Influenza Vaccines.

Authors:  Wey Wen Lim; Nancy H L Leung; Sheena G Sullivan; Eric J Tchetgen Tchetgen; Benjamin J Cowling
Journal:  Am J Epidemiol       Date:  2020-03-02       Impact factor: 4.897

4.  Protein Vaccination Directs the CD4+ T Cell Response toward Shared Protective Epitopes That Can Be Recalled after Influenza Virus Infection.

Authors:  Ajitanuj Rattan; Katherine A Richards; Zackery A G Knowlden; Andrea J Sant
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

5.  Validation of a Harmonized Enzyme-Linked-Lectin-Assay (ELLA-NI) Based Neuraminidase Inhibition Assay Standard Operating Procedure (SOP) for Quantification of N1 Influenza Antibodies and the Use of a Calibrator to Improve the Reproducibility of the ELLA-NI With Reverse Genetics Viral and Recombinant Neuraminidase Antigens: A FLUCOP Collaborative Study.

Authors:  Marie-Clotilde Bernard; Joanna Waldock; Sylvie Commandeur; Lea Strauß; Claudia Maria Trombetta; Serena Marchi; Fan Zhou; Serge van de Witte; Peter van Amsterdam; Sammy Ho; Katja Hoschler; Vladimir Lugovtsev; Jerry P Weir; Emanuele Montomoli; Rebecca J Cox; Othmar G Engelhardt; Damien Friel; Ralf Wagner; Thierry Ollinger; Sophie Germain; Hanna Sediri-Schön
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

6.  The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4+ T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway.

Authors:  Sonia Jain; Parakkal Jovvian George; Wanyan Deng; Joseph Koussa; Kaela Parkhouse; Scott E Hensley; Jiu Jiang; Jie Lu; Zhuyun Liu; Junfei Wei; Bin Zhan; Maria Elena Bottazzi; Hao Shen; Sara Lustigman
Journal:  Vaccine       Date:  2018-06-14       Impact factor: 3.641

7.  Impact of erythrocyte species on assays for influenza serology.

Authors:  C M Trombetta; C Ulivieri; R J Cox; E J Remarque; C Centi; D Perini; G Piccini; S Rossi; S Marchi; E Montomoli
Journal:  J Prev Med Hyg       Date:  2018-03-30

Review 8.  Molecular Signatures of Immunity and Immunogenicity in Infection and Vaccination.

Authors:  Mariëlle C Haks; Barbara Bottazzi; Valentina Cecchinato; Corinne De Gregorio; Giuseppe Del Giudice; Stefan H E Kaufmann; Antonio Lanzavecchia; David J M Lewis; Jeroen Maertzdorf; Alberto Mantovani; Federica Sallusto; Marina Sironi; Mariagrazia Uguccioni; Tom H M Ottenhoff
Journal:  Front Immunol       Date:  2017-11-15       Impact factor: 7.561

9.  Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.

Authors:  David P Greenberg; Corwin A Robertson; H Keipp Talbot; Michael D Decker
Journal:  Hum Vaccin Immunother       Date:  2017-09-02       Impact factor: 3.452

10.  Do Vaccines Need a Gender Perspective? Influenza Says Yes!

Authors:  Laura Sánchez-de Prada; Raúl Ortiz de Lejarazu-Leonardo; Javier Castrodeza-Sanz; Eduardo Tamayo-Gómez; José María Eiros-Bouza; Iván Sanz-Muñoz
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.